Cocktails for cancer with a measure of immunotherapy

Nature. 2016 Apr 14;532(7598):162-4. doi: 10.1038/532162a.
No abstract available

Publication types

  • News

MeSH terms

  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • CD40 Antigens / antagonists & inhibitors
  • CTLA-4 Antigen / antagonists & inhibitors
  • CTLA-4 Antigen / immunology
  • Cancer Vaccines / administration & dosage
  • Cancer Vaccines / immunology
  • Cancer Vaccines / therapeutic use
  • Child
  • Clinical Trials as Topic
  • Endpoint Determination
  • Epigenesis, Genetic / drug effects
  • Humans
  • Immunotherapy* / trends
  • Ipilimumab
  • Melanoma / drug therapy
  • Melanoma / immunology
  • Mice
  • Neoplasms / drug therapy*
  • Neoplasms / immunology*
  • Neoplasms / therapy
  • Nivolumab
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • Survivors
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Monoclonal
  • CD40 Antigens
  • CTLA-4 Antigen
  • Cancer Vaccines
  • Ipilimumab
  • Nivolumab